Canada Life’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $360K | Buy |
28,080
+3,928
| +16% | +$50K | ﹤0.01% | 1535 |
|
|
2025
Q4 | $217K | Sell |
24,152
-875
| -3% | -$12K | ﹤0.01% | 1607 |
|
|
2025
Q3 | $423K | Buy |
25,027
+3,275
| +15% | +$40.3K | ﹤0.01% | 1628 |
|
|
2025
Q2 | $204K | Buy |
21,752
+10,283
| +90% | +$84.4K | ﹤0.01% | 1701 |
|
|
2025
Q1 | $82K | Sell |
11,469
-14,077
| -55% | -$142K | ﹤0.01% | 1807 |
|
|
2024
Q4 | $298K | Buy |
25,546
+82
| +0.3% | +$1.28K | ﹤0.01% | 1708 |
|
|
2024
Q3 | $524K | Sell |
25,464
-517
| -2% | -$11.9K | ﹤0.01% | 1665 |
|
|
2024
Q2 | $582K | Sell |
25,981
-1,630
| -6% | -$38.8K | ﹤0.01% | 1648 |
|
|
2024
Q1 | $759K | Buy |
27,611
+330
| +1% | +$9.17K | ﹤0.01% | 1571 |
|
|
2023
Q4 | $826K | Buy |
27,281
+3,632
| +15% | +$104K | ﹤0.01% | 1562 |
|
|
2023
Q3 | $747K | Buy |
23,649
+5,592
| +31% | +$217K | ﹤0.01% | 1578 |
|
|
2023
Q2 | $741K | Sell |
18,057
-1,150
| -6% | -$46.6K | ﹤0.01% | 1579 |
|
|
2023
Q1 | $717K | Buy |
19,207
+3,498
| +22% | +$137K | ﹤0.01% | 1597 |
|
|
2022
Q4 | $551K | Buy |
15,709
+6,154
| +64% | +$293K | ﹤0.01% | 1696 |
|
|
2022
Q3 | $534K | Buy |
9,555
+6,102
| +177% | +$379K | ﹤0.01% | 1665 |
|
|
2022
Q2 | $178K | Buy |
3,453
+36
| +1% | +$1.83K | ﹤0.01% | 1835 |
|
|
2022
Q1 | $264K | Sell |
3,417
-36
| -1% | -$3.05K | ﹤0.01% | 1833 |
|
|
2021
Q4 | $407K | Buy |
3,453
+33
| +1% | +$4.13K | ﹤0.01% | 1745 |
|
|
2021
Q3 | $462K | Hold |
3,420
| – | – | ﹤0.01% | 1745 |
|
|
2021
Q2 | $553K | Buy |
3,420
+533
| +18% | +$41.5K | ﹤0.01% | 1720 |
|
|
2021
Q1 | $230K | Sell |
2,887
-524
| -15% | -$35.2K | ﹤0.01% | 1909 |
|
|
2020
Q4 | $185K | Buy |
3,411
+1,023
| +43% | +$37.1K | ﹤0.01% | 1982 |
|
|
2020
Q3 | $47K | Hold |
2,388
| – | – | ﹤0.01% | 2195 |
|
|
2020
Q2 | $50K | Hold |
2,388
| – | – | ﹤0.01% | 2220 |
|
|
2020
Q1 | $29K | Hold |
2,388
| – | – | ﹤0.01% | 2288 |
|
|
2019
Q4 | $35K | Buy |
+2,388
| New | +$33.2K | ﹤0.01% | 2383 |
|
|
2019
Q3 | – | Sell |
-4,500
| Closed | -$73K | – | 1876 |
|
|
2019
Q2 | $73K | Hold |
4,500
| – | – | ﹤0.01% | 2326 |
|
|
2019
Q1 | $77K | Hold |
4,500
| – | – | ﹤0.01% | 2145 |
|
|
2018
Q4 | $59K | Sell |
4,500
-40,610
| -90% | -$755K | ﹤0.01% | 2313 |
|
|
2018
Q3 | $1.3M | Sell |
45,110
-51,921
| -54% | -$1.51M | ﹤0.01% | 1412 |
|
|
2018
Q2 | $2.65M | Buy |
97,031
+2,395
| +3% | +$58K | 0.01% | 981 |
|
|
2018
Q1 | $2M | Buy |
94,636
+93,236
| +6,660% | +$2.29M | ﹤0.01% | 1156 |
|
|
2017
Q4 | $27K | Hold |
1,400
| – | – | ﹤0.01% | 2468 |
|
|
2017
Q3 | $34K | Hold |
1,400
| – | – | ﹤0.01% | 2416 |
|
|
2017
Q2 | $22K | Hold |
1,400
| – | – | ﹤0.01% | 2485 |
|
|
2017
Q1 | $20K | Hold |
1,400
| – | – | ﹤0.01% | 2460 |
|
|
2016
Q4 | $18K | Buy |
+1,400
| New | +$21K | ﹤0.01% | 2501 |
|
Other funds holding NTLA
AIM
VPM
VCM
RP
Canada Life's NTLA Position: Q1 2026 in Review
Canada Life increased its Intellia Therapeutics (NTLA) stake by 16% in Q1 2026, buying an estimated $50K and bringing the position to 28,080 shares worth $360K. The position accounts for ﹤0.01% of the portfolio, ranked #1535.
Canada Life first reported a position in NTLA in Q4 2016 and has held it in 37 quarters since. The position peaked at $2.65M in Q2 2018. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.
- Canada Life held 28,080 shares of Intellia Therapeutics worth $360K as of Q1 2026.
- Canada Life bought 3,928 Intellia Therapeutics shares in Q1 2026, an estimated $50K.
- Intellia Therapeutics made up ﹤0.01% of Canada Life's portfolio in Q1 2026, its #1535 holding.
- Canada Life first reported a position in Intellia Therapeutics in Q4 2016 and has held it in 37 quarters since.
- Canada Life's Intellia Therapeutics position peaked at $2.65M in Q2 2018.
- 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.
Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.